Recent Publications

Click publication title for access to PDF

Research Presented at the Annual ACTRIMS Meeting

Virtual Conference — February 25- 27, 2021


Analytical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

W. Hu¹, L. Loh¹, H. Patel¹, M. DeGuzman¹, M. Becich¹, F. Rubio da Costa¹, V. Gehman¹, E. Assarsson², S.Ohlsson², M. Lundberg², J. Bergman², N. Nordberg², F. Qureshi¹
¹Octave Bioscience, Inc., Menlo Park, CA, USA,²Olink Proteomics, Uppsala, Sweden.


Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

T. Chitnis¹, C. Ionete², N. El Ayoubi³, S. Saxena¹, P. Gaitan-Walsh¹, H. Lokhande¹, A. Paul¹, F. Saleh¹, H. Weiner¹, F.Qureshi4, M. J. Becich4, F. Rubio da Costa4, V.M. Gehman4, S. J. Khoury³
¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²University of Massachusetts Medical School, Worcester, MA,³American University of Beirut, Beirut, Lebanon,4Octave Bioscience, Menlo Park, CA.


Integrated Analysis of Novel MRI and Blood Serum Biomarkers for the Estimation and Prediction of MS Disease Activity and Progression

Jens Kuhle¹, David Leppert¹, Johanna Oechtering¹, Pascal Benkert¹, Annette Orleth¹, Özgür Yaldizli¹,Victor Gehman², Michael Becich², Ferhan Qureshi², Fatima Rubio da Costa², Kelly Leyden², Anisha Keshavan²,Cristina Granziera¹
¹University Hospital Basel, Switzerland;²Octave Bioscience, Menlo Park, CA, USA


Proteomic Serum Biomarker Signatures Associated with Patient Reported Outcomes in Multiple Sclerosis

M. Becich*², F. Qureshi², K. Leyden², Z. Xia¹
¹University of Pittsburgh, Pittsburgh, PA, USA; ²Octave Bioscience, Menlo Park, CA, USA


Changes in the Detection of Clinically Relevant White Matter Lesions in MS Using FDA-Cleared Automated Software

Kelly Leyden MRes¹, Anisha Keshavan PhD¹, Victor Gehman PhD¹, Michael Iv MD¹,2
¹Octave Bioscience, Menlo Park, CA, United States of America, 2Stanford University, CA, United States of America

Research Presented at the Joint ACTRIMS-ECTRIMS Meeting

MS Virtual 2020 — September 11-13, 2020


Development of a Custom Multivariate Proteomic Serum Based Assay for Association with Radiographic and Clinical Endpoints in MS

Tanuja Chitnis¹, Michael Becich², Riley Bove³, Bruce A.C. Cree³, Victor Gehman², Refugia Gomez³, Stephen L. Hauser³, Roland Henry³, Amal Katrib², Hrishikesh Lokhande¹, Jorge R. Oksenberg³, Anu Paul¹, Ferhan Qureshi², Adam Santaniello³, Neda Sattarnezhad4, Shrishti Saxena¹, Howard Weiner¹, Michael Wilson³, Hajime Yano¹, Sergio E. Baranzini³
¹Brigham and Women’s Hospital, Boston, MA, USA,  ²Octave Bioscience, Menlo Park, CA, USA,  ³University of California San Francisco, CA, USA,  4University of Illinois at Chicago, IL, USA


Cross-sectional and longitudinal estimation of radiographic and clinical endpoints to quantify MS disease trajectory with blood serum protein levels.

Jens Kuhle¹, David Leppert¹, Pascal Benkert¹, Johanna Oechtering¹, Annette Orleth¹, Özgür Yaldizli¹, Michael Becich², Victor Gehman², Amal Katrib², Fatima Rubio da Costa², Ferhan Qureshi², Cristina Granziera¹
¹University Hospital Basel, Switzerland, ²Octave Bioscience, Menlo Park, CA, United States of America


From proteome to interactome: a mechanistic approach to MS biomarker discovery

Amal Katrib¹,  Ferhan Qureshi¹,  Michael Becich¹,  Victor Gehman¹,  Susan Goelz²
¹Octave Bioscience, Menlo Park, CA, USA,  ²Myelin Repair Foundation, Saratoga, CA, USA


Improving Patient Outcomes through a Comprehensive Care Management Platform Measuring Outcomes and Value: an Integrated, Novel solution for Generating insights in MS (MOVING MS)

Annalise Miner¹,  Michael Becich²,  Victor Gehman PhD²,  Jennifer Graves MD¹
¹University of California San Diego, CA, USA,  ²Octave Bioscience, Menlo Park, CA, USA


Improved detection of clinically relevant MRI findings in Multiple Sclerosis radiology reports using FDA-approved quantitative software

Kelly Leyden MRes¹,  Anisha Keshavan PhD¹,  Michael Iv MD1,2
¹Octave Bioscience, Menlo Park, CA, USA,  ²Stanford University, CA, USA


BrainGraph: A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

David Hughes BSN¹,  Weidong Yang PhD²,  Kelly Leyden MRes¹,  Michael Iv MD1,3,  Anisha Keshavan PhD¹
¹Octave Bioscience, Menlo Park, CA, USA, ²Kineviz, San Francisco, CA, USA,  ³Stanford University, CA, USA


High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

Anisha Keshavan PhD¹,  Kelly M. Leyden¹,  Barbara Dappert MD¹,  Michael Iv MD1,2,  Michael Becich¹,  Michael Towbin¹,  David Hughes BSN¹,  Annalise Miner¹,  Revere Kinkel MD³,  Jennifer Graves MD³
¹Octave Bioscience, Menlo Park, CA, USA,  ²Stanford University, CA, USA,  ³University of California, San Diego, CA, USA

Research Presented at ECTRIMS 2019
Stockholm, Sweden — September 11-13, 2019


Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone

T. Chitnis1, H. Yano1, S. Saxena1, H. Lokhande1, N. Sattarnezhad1, M.C. Manieri1, A. Paul1, F. Saleh1, M. Collins1, B. Glanz1, C. Guttmann1, R. Bakshi1, F. Qureshi2, M. Becich2, R. Osan2, V. Gehman2, H. Weiner1
1Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, 2Octave Bioscience, Menlo Park, CA, United States

Classification of high versus low annualized relapse rate status in subjects with relapsing-remitting multiple sclerosis using multivariate serum protein biomarker models

N. Sattarnezhad1, S. Saxena1, C. Gonzalez1, H. Lokhande1, B. Glanz1, F. Qureshi2, M. Becich2, R. Osan2, H. Weiner1, T. Chitnis1
1Partners MS Center, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA 2Octave Bioscience, Menlo Park, CA, USA